UBS Maintains Neutral on Chemours, Lowers Price Target to $16
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.